| 发明名称 | Chemosensory receptor ligand-based therapies | ||
| 摘要 | Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention. | ||
| 申请公布号 | US9526741(B2) | 申请公布日期 | 2016.12.27 |
| 申请号 | US201414480399 | 申请日期 | 2014.09.08 |
| 申请人 | AMBRA BIOSCIENCE LLC | 发明人 | Baron Alain;Brown Martin R.;Jones Christopher R. G. |
| 分类号 | A61K31/13;A61K31/20;A61K31/7016;A61K31/195;A61K31/235;A61K31/35;A61K31/352;A61K31/70;A61K31/198;A61K31/202;A61K31/4709;A61K31/575;A61K45/06 | 主分类号 | A61K31/13 |
| 代理机构 | Arnold & Porter LLP | 代理人 | Arnold & Porter LLP ;Lorenz Todd A. |
| 主权项 | 1. A method of increasing the circulating concentration of one or more of GLP-1 (total), GLP-1 (active), PYY (total), PYY 3-36, and insulin in a subject comprising administering orally a composition comprising a non-nutritive sweet receptor agonist, wherein said composition is adapted to release said non-nutritive sweet receptor agonist to one or more regions of the intestine of a subject selected from the group consisting of the duodenum, jejunum, ileum, caecum, colon, rectum, and combinations thereof. | ||
| 地址 | San Diego CA US | ||